Precio Mydecine Innovations Group Inc (MYCOD)

Mydecine Innovations Group Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2014-08-18. Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The firm is engaged in developing the next generation of medications and therapies to address mental health disorders, such as nicotine addiction and post traumatic stress disorder (PTSD). The firm conducts research and development on novel second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The firm has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The firm is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). The company uses advanced artificial intelligence (AI) and machine learning to design and screen drugs of interest. Its subsidiaries include Mydecine Group (1220611 BC Ltd) and NeuroPharm Inc.